



Carafate® (sucralfate) – First-time generic

- On December 3, 2019, [Amneal Pharmaceuticals](#) announced the launch of an [AB-rated](#) generic version of Allergan's [Carafate \(sucralfate\)](#) oral suspension.
- Carafate is approved for the short-term (up to 8 weeks) treatment of active duodenal ulcer.
- Sucralfate is also available generically as a [tablet](#).
 - Sucralfate tablet carries the same indication as the suspension and is also approved for maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
- According to IQVIA™, U.S annual sales for Carafate oral suspension was estimated to be approximately \$285 million for the 12 months ending on October 31, 2019.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.